Inspirna Overview

  • Founded
  • 2010
Founded
  • Status
  • Private
  • Employees
  • 21
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $6M
Latest Deal Amount
  • Investors
  • 17

Inspirna General Information

Description

Developer of novel cancer drugs intended to target key pathways in cancer progression. The company's drugs identify novel cancer targets that drive tumor growth and cancer progression using a microRNA-based target discovery platform and treats it via an oral small molecule cancer metabolism inhibitor, enabling cancer patients to get optimal cure using drugs that target using small molecules and antibodies.

Contact Information

Formerly Known As
Rgenix, Inc., Rgenix Incorporated, Rgenix
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 310 East 67th Street
  • Suite 1-12
  • New York, NY 10065
  • United States
+1 (646) 000-0000

Inspirna Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Inspirna Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series C) 24-Feb-2021 $6M 000.00 00000 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series C) 09-Oct-2018 0000 000.00 00000 Completed Clinical Trials - Phase 1
4. Later Stage VC 03-Jun-2016 0000 000.00 0000 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 31-Jul-2015 000 000.00 0000 Completed Pre-Clinical Trials
2. Grant 11-Aug-2014 $200K $2.5M Completed Pre-Clinical Trials
1. Seed Round 30-Sep-2013 $2.5M $2.5M 00.00 Completed Pre-Clinical Trials
To view Inspirna’s complete valuation and funding history, request access »

Inspirna Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 13,889,841 $0.000100 $0.61 $0.61 1x $0.61 6.9%
Seed 5,869,618 $0.000100 $0.53 $0.53 1x $0.53 2.92%
To view Inspirna’s complete cap table history, request access »

Inspirna Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel cancer drugs intended to target key pathways in cancer progression. The company's drugs identify nove
Drug Discovery
New York, NY
21 As of 2021
000.00
0000 0000-00-00
00000000000 000.00

000000

adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
0000 000000000
Ann Arbor, MI
00 As of 0000
00000
000000 - 000 00000

00000000

et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut a
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Inspirna Competitors (27)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lycera Venture Capital-Backed Ann Arbor, MI 00 00000 000000 - 000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000 00000000000 Formerly VC-backed Burlingame, CA 00 00000 000000 - 000 00000
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 000000000 - 00000
00000 000000000000 Formerly VC-backed Waltham, MA 000 00000 00000000 00000
You’re viewing 5 of 27 competitors. Get the full list »

Inspirna Patents

Inspirna Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11174220-B2 Metal salts and uses thereof Active 13-Dec-2019 0000000000 000
US-20210179539-A1 Metal salts and uses thereof Granted 13-Dec-2019 000000000
US-20210177790-A1 Methods of treating cancer Pending 11-Dec-2019 0000000000
CA-3130303-A1 High-affinity anti-mertk antibodies and uses thereof Pending 26-Feb-2019 000000000
US-20200291135-A1 High-affinity anti-mertk antibodies and uses thereof Pending 26-Feb-2019 C07K16/40
To view Inspirna’s complete patent history, request access »

Inspirna Executive Team (17)

Name Title Board Seat Contact Info
Masoud Tavazoie Ph.D Co-Founder, Board Member and Chief Executive Officer
Sohail Tavazoie Ph.D Co-Founder & Chairman of Scientific Advisory Board
Saeed Tavazoie Ph.D Co-Founder & Board Member
Steven Wald Senior Vice President of Chemistry & Pharmaceutical Sciences
Michael Szarek Ph.D Vice President of Clinical & Regulatory Affairs
You’re viewing 5 of 17 executive team members. Get the full list »

Inspirna Board Members (13)

Name Representing Role Since
Antoine Papiernik Sofinnova Partners Board Member 000 0000
David Darst Self Chief Operating Officer & Board Observer 000 0000
Dieter Weinand Inspirna Chairman 000 0000
Eric Rowinsky MD Self Board Member & Executive Chairman 000 0000
Jue Pu Inspirna Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Inspirna Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Inspirna Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bolur Holdings Impact Investing Minority 000 0000 000000 0
EXOR Seeds Venture Capital Minority 000 0000 000000 0
Lepu Medical Corporation Minority 000 0000 000000 0
Oceanpine Capital Venture Capital Minority 000 0000 000000 0
Oceanpine Healthcare Fund Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 17 investors. Get the full list »